Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 243 results found since Jan 2013.
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research
Structural Framework for Analysis of CD4+ T-Cell Epitope Dominance in Viral Fusion Proteins
Biochemistry. 2023 Aug 9. doi: 10.1021/acs.biochem.3c00335. Online ahead of print.ABSTRACTAntigen conformation shapes CD4+ T-cell specificity through mechanisms of antigen processing, and the consequences for immunity may rival those from conformational effects on antibody specificity. CD4+ T cells initiate and control immunity to pathogens and cancer and are at least partly responsible for immunopathology associated with infection, autoimmunity, and allergy. The primary trigger for CD4+ T-cell maturation is the presentation of an epitope peptide in the MHC class II antigen-presenting protein (MHCII), most commonly on an a...
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Samuel J Landry Ramgopal R Mettu Jay K Kolls Judith H Aberle Elizabeth Norton Kevin Zwezdaryk James Robinson Source Type: research
The Conspirituality of Robert F. Kennedy Jr.
This article has been adapted from Chapter 23 of Conspirituality: How New Age Conspiracy Theories Became a Health Threat by Derek Beres, Matthew Remski, and Julian Walker. Copyright © 2023. Available from PublicAffairs, an imprint of Hachette Book Group, Inc.
Source: TIME: Health - July 5, 2023 Category: Consumer Health News Authors: Derek Beres, Matthew Remski, and Julian Walker Tags: Uncategorized freelance politics Source Type: news
Updated Guidance Regarding The Risk ofAllergic Reactions to COVID-19 Vaccines and Recommended Evaluation and Management: A GRADE Assessment, and International Consensus Approach
J Allergy Clin Immunol. 2023 Jun 7:S0091-6749(23)00746-7. doi: 10.1016/j.jaci.2023.05.019. Online ahead of print.ABSTRACTThis guidance updates 2021 GRADE recomendations regarding immediate allergic reactions following COVID-19 vaccines and addresses re-vaccinating individuals with 1st dose allergic reactions and allergy testing to determine re-vaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 re-vaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reac...
Source: Clinical Lung Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Matthew Greenhawt Timothy E Dribin Elissa M Abrams Marcus Shaker Derek K Chu David Bk Golden Cem Akin Akterini Anagnostou Faisal ALMuhizi Waleed Alqurashi Peter Arkwright James L Baldwin Aleena Banerji Philippe B égin Moshe Ben-Shoshan Jonathan Bernstein Source Type: research
The COVID-19 virus mutated to outsmart key antibody treatments. Better ones are coming
In 2020, as the COVID-19 pandemic raged and other effective drugs were elusive, monoclonal antibodies (mAbs) emerged as a lifesaving treatment. But now, 3 years later, all the approvals for COVID-19–fighting antibodies have been rescinded in the United States, as mutations of the SARS-CoV-2 virus have left the drugs—which target parts of the original virus—ineffective.
Researchers around the globe are now trying to revive antibody treatments by redesigning them to take aim at targets that are less prone to mutation. “There are new approaches that present a much more challenging task for the virus to evade,” ...
Source: ScienceNOW - May 24, 2023 Category: Science Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news
Utilizing Biologics in Drug Desensitization
AbstractPurpose of ReviewThe purpose of this literature review was to review the latest advancements with biologics in rapid drug desensitization. Our methodology was to highlight both desensitization to biologics themselves and the use of biologics in desensitization to both biologic and nonbiologic drugs.Recent FindingsBiologics are a vast category of drugs that include monoclonal antibodies, nanobodies, modern vaccinations, and even hormones. Desensitization to biologics can be safely performed through standardized procedure. Biomarkers are used both in vitro and in vivo to help identify and classify hypersensitivity re...
Source: Current Allergy and Asthma Reports - November 29, 2022 Category: Allergy & Immunology Source Type: research
In vitro and in vivo Evidence on Intra-tumor Injection of Allogeneic Serum for Immunotherapy in a Mouse Model of Colon Cancer
Iran J Allergy Asthma Immunol. 2022 Oct 26;21(5):549-560. doi: 10.18502/ijaai.v21i5.11042.ABSTRACTIt is believed that preformed antibodies are responsible for blood transfusion reactions and transplant rejections. In order to remove a tumor, the tissue must be rejected. On the basis of transfusion reaction and transplantation immunology, we hypothesized that allogeneic serum can inhibit tumor growth when injected intra-tumor. Initially, an in vitro cytotoxicity test was conducted using the C57BL/6 serum (intact or decomplemented) in combination with the BALB/c-originating CT26 cell line. The CT26 cell line was used to esta...
Source: Cancer Control - November 7, 2022 Category: Cancer & Oncology Authors: Erfan Basirat Danial Dehghan Ardeshir Abbasi Nafiseh Pakravan Source Type: research
